Strategic collaborations Leverage recent partnerships with Piramal Pharma Solutions to position Ajinomoto Bio-Pharma Services as a preferred CDMO for integrated biopharma programs, offering end-to-end manufacturing capabilities from gene therapy to HPAPI across multiple global sites.

ADC leadership Highlight award-winning AJICAP linker technology and recognized ADC preclinical excellence to attract biotech clients developing antibody-drug conjugates, offering specialized conjugation services, purification, and scalable manufacturing.

Global capacity Emphasize multi-site presence in Belgium, USA, Japan, and India to handle international programs, enabling global supply continuity, regional regulatory support, and scalable manufacturing for large and small molecules including HPAPI and oligonucleotides.

Technology stack Promote advanced platforms such as Corynex protein expression, continuous flow manufacturing, biocatalysis, and oligonucleotide synthesis as differentiators for complex programs, appealing to sponsors seeking innovative and efficient production solutions.

Growth potential Target mid-to-large biopharma and CDMO partners seeking expansion in ADC, gene therapy, and complex API programs, leveraging recent press coverage and leadership in performance awards to drive outbound opportunities and formalized collaborations.